SQUAWK/NEWS
Account
Theme
Account
Menu
Live News EQUITY FLASH L impact

Biogen Study Reports 76% Lower Alzheimer’s Progression Rate in LEQEMBI Analysis

Biogen reported three-year real-world findings from 560 patients at 13 U.S. sites. A pre-specified analysis found a 76% lower rate of progression to moderate or severe Alzheimer’s disease dementia with LEQEMBI versus a matched natural history cohort.

BIIB

Related stories